TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ClariFix Cryoablation Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is \>21 years of age~2. Subject has had moderate to severe symptoms of rhinorrhea and/or nasal congestion for \>3 months (rTNSS rating of 2 or 3)~3. Subject has signed IRB-approved informed consent form~Exclusion Criteria:~1. Subject has clinically significant anatomic obstructions that limit access to the posterior nose including severe septal deviation, nasal polyps, and sinonasal tumor~2. Subject has a septal perforation~3. Subject has had prior sinus or nasal surgery that significantly alters the anatomy of the posterior nose~4. Subject has had prior head or neck irradiation~5. Subject has active or chronic nasal or sinus infection~6. Subject has active coagulation disorder or patient is receiving anti-coagulants which cannot be safely stopped for 2 weeks~7. Subject has a history of dry nose symptoms~8. Subject is pregnant or lactating~9. Subject is participating in another clinical research study~10. Subject has an allergy or intolerance to anesthetic agent~11. Subject is an active smoker or has been a smoker within the last 6 months~12. Any physical condition that in the investigator's opinion would prevent adequate study participation or pose increased risk

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Cryoablation with the ClariFix device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Fenofibrate for Primary Biliary Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of PBC by serological (positive antimitochondrial antibodies) and/or histological evidence (diagnostic liver biopsy)~* Previous treatment with UDCA 13-15 mg/kg/day for at least 1 year~* Persistent elevation of serum alkaline phosphatase ≥ 2 times the upper limit of normal on two separate measurements~* Female patients of childbearing age should have a pregnancy test done within -days of the beginning of this trial, and should agree to be on adequate contraception throughout the study period~* Signed informed consent after careful review of the information and study details by one of the investigators~Exclusion Criteria~* Hypersensitivity to fenofibrate~* Prisoners and institutionalized subjects~* Pregnant or nursing women~* Anticipated need for liver transplantation in one year (estimated one year survival \< 80%) as determined by the Mayo risk score. The Mayo risk score takes into account the patient's age, serum bilirubin, albumin and prothrombin time, as well as presence or absence of peripheral edema.~* Recipients of liver transplantation~* Recurrent variceal hemorrhage, uncontrolled encephalopathy or refractory ascites~* Co-existing liver diseases, such as primary sclerosing cholangitis, acute or chronic hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, cholangiocarcinoma~* Acute or chronic renal failure~* Known history of cholecystitis with intact gallbladder~* Current use of statins, as the concomitant use of fibrates and statins would increase the risk of toxicity

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Patients treated with Fenofibrate (Type: EXPERIMENTAL): Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of A-T~* significant functional disability~* age over 4 years~Exclusion Criteria:~* major comorbidity: active malignancy requiring chemotherapy, kidney or liver failure~* sexually active~* known hypersensitivity to amantadine~* previous treatment with amantadine in the 2 months preceding the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 50 Months
- Healthy Volunteers: f

Study Arms:
- amantadine (PKMERZ) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Pentaxim in South African Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged \< 24 hours on the day of inclusion~Exclusion Criteria:~* At visit 01 (screening)~* Illness at a stage that could interfere with trial conduct or completion.~* Any vaccination preceding the trial participation (except Bacille Calmette-Guerin \[BCG\])~* Acute illness on the day of screening. At visit 01 and visit 02 (screening and first study vaccination).~* Planned participation in another clinical trial during the present trial period~* Blood or blood-derived products received since birth.~* Mother known as seropositive to HIV or hepatitis B.~* Known thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current seizures at visit 02 (first study vaccination)~* Participation in another clinical trial preceding the first trial vaccination~* Congenital or acquired immunodeficiency; immunosuppressive therapy such as long-term systemic corticosteroid therapy.~* Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion.~* Any vaccination preceding the first trial vaccination (except BCG)~* History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b and hepatitis B infection (confirmed either clinically, serologically or microbiologically).~* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b and hepatitis B infection with the trial vaccine or another vaccine.~* Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) or acute illness on the day of first vaccination

- Gender: ALL
- Minimum Age: 24 Hours
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid organ transplant recipient.~* Age ≥18 years~* VZV-seronegative at time of transplant~* ≥90 days post-transplant~* Able to provide informed consent~Exclusion Criteria:~* Has already received the recombinant subunit Herpes zoster vaccine in the past~* Ongoing CMV viremia \> 200 IU/mL~* HIV infection~* Diagnosis of malignancy (e.g. PTLD)~* History of a severe allergic reaction (anaphylactic reaction) after any vaccine~* Documented Chickenpox or Shingles after transplantation~* Congenital immunodeficiency (e.g., CVID)~* Treatment for rejection in the past 30 days~* Immunoglobulin in the past 30 days or anticipated to receive immunoglobulin~* Anti-CD20 monoclonal antibody in the past 6 months or anticipated to receive Anti-CD20 monoclonal antibody~* Plasmapheresis in the past 30 days or anticipated to receive plasmapheresis~* Febrile illness in the past one week~* Unable to comply with the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VZV seronegative Transplant Patients (Type: EXPERIMENTAL): recombinant subunit Herpes zoster vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years and Age ≤75 years;~* Scheduled for laparoscopic gastrointestinal surgical procedure with general anesthesia ;~* The score evaluated by Apfel simplified PONV risk assessment systems is ≥3.~Exclusion Criteria:~* The American Society of Anesthesiologists (ASA) rating is \>3;~* Severe hepatic dysfunction(the score of Child-Pugh is \>9);~* With contraindications for using fosaprepitant, 5-HT3 receptor antagonist or dexamethasone ;~* Take medications with known antiemetic properties preoperatively ;~* With mental disorder, or not be able to communicate ;~* Pregnant women or nursing mothers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- triple therapy (Type: EXPERIMENTAL): Triple combination of Fosaprepitant, Palonosetron and Dexamethasone were administered
- double therapy (Type: OTHER): double combination of Palonosetron and Dexamethasone were administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* obese and overweight, BMI 25-50, HbA1C \<10%~Exclusion Criteria:~* Preexisting, clinically significant cardiovascular, liver, renal, or GI disease that is considered unstable; pregnancy, Type 1 diabetes; Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO (Type: EXPERIMENTAL): Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
- Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO (Type: EXPERIMENTAL): Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
- Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO (Type: EXPERIMENTAL): Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
- Part A: LIK066 + P1: 8% CHO (Type: EXPERIMENTAL): Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
- Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC (Type: EXPERIMENTAL): Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
- Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS (Type: EXPERIMENTAL): Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
- Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS (Type: EXPERIMENTAL): Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA for \>= 3 months.~* Subjects must have been on oral or parenteral MTX therapy \>= 3 months and on a stable dose for \>= 4 weeks prior to first dose of study drug.~* Must have discontinued all conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (other than MTX) \>= 4 weeks prior to first dose of study drug.~* Meets the following minimum disease activity criteria: \>= 6 swollen joints (based on 66 joint counts) and \>= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.~Exclusion Criteria:~* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).~* Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).~* Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.
- Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.
- Methotrexate / Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.
- Methotrexate / Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Guanfacine to Improve Substance Use Outcomes in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 100 treatment seeking women~* Ages 18-70 years~* Body mass index (BMI) of 18-35~* Meet current DSM-V criteria for co-occurring SUDs, with primary DSM-V cocaine or primary DSM-V opioid use disorder AND co-occurring cannabis or alcohol or nicotine use disorders;~* Positive drug urine toxicology screens for primary addictive disorder during a 2-week intake assessment period~* Good health as verified by screening examination~* Able to read English and complete study evaluations~* Able to provide informed written and verbal consent~Exclusion Criteria:~* Meet criteria for physiological dependence on alcohol requiring medical detoxification~* Regular use of anti-hypertensives, anti-arrythmics, antiretroviral medications, and medications that would interact with Guanfacine and be contraindicated as per study physician;~* Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)~* Significant underlying medical conditions which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study; Specifically hepatic and renal impairment as per liver enzymes at 3X the normal limit, or BUN\>50mg or BUN:Cr \> 10:1.~* Hypotensive women with sitting blood pressure below 100/50 mmHG~* Women who are pregnant, nursing or refuse to use a reliable form of birth control~* EKG evidence at baseline screening of any clinically significant conduction abnormalities, including a Bazlett's QT c\>470 msec for women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Study Medication (Type: EXPERIMENTAL): guanfacine 3mg/day (GUA)
- placebo (Type: PLACEBO_COMPARATOR): placebo (PBO)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Previous diagnosis of Type 2 diabetes(more than 3months)~* Patients aged over 18 years~* FPG levels in the range : 126 - 270mg/dL or HbA1c : 7.0 - 12.0%~Exclusion Criteria:~* Pregnant women, Breast feeding, or actively trying to be come pregnant~* Patients with Type 1 DM, gestational diabetes or secondary diabetes~* FPG levels in the range : ≥ 270mg/dL HbA1c : \< 7.0, \>12.0%~* Patient who take the medicine which may affect to blood sugar control (i.e.systemic glucocorticoid)~* Patients with diabetic complications or the history of a case that would affect to efficacy and safety evaluation (i.e. Thyroid disorder, Cushing's Syndrome, Multiple ovarian cystoma, pheochromocytoma)~* Patients with Chronic hepatitis, hepatitis B, C (except healthy HBV carrier) or Liver diseases (AST or/and ALT \>2 × ULN(upper limit normal))~* Patients with Kidney disorder (Cr\>2.0)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): YY-351, PO, 1T tid. / Placebo, 1T tid.
- 2 (Type: EXPERIMENTAL): YY-351. PO, 2T bid. / Placebo 2T qd.
- 3 (Type: EXPERIMENTAL): YY-351, PO, 2T tid.
- 4 (Type: PLACEBO_COMPARATOR): Placebo, PO, 2T tid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cingal Study for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is 40 - 75 years old with a Body Mass Index (BMI)≤ 40 kg/m2~* Subject has Kellgren-Lawrence (K-L) severity grade I, II, or III in the index knee as determined by X-Ray. Contralateral knee: K-L severity grade 0, I, or II.~Exclusion Criteria:~* Subject received an intra-articular (IA) injection of Hyaluronic Acid (HA) and/or steroid in either knee within 6 months of signing the informed consent form (ICF).~* Subject had an arthroscopy of either knee within 3 months of signing the informed consent form (ICF).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saline (Type: PLACEBO_COMPARATOR): Single injection of 0.9% saline supplied as a 4 milliliter (mL) unit dose in a 5mL glass syringe
- Hyaluronic Acid and TH (Cingal®) (Type: EXPERIMENTAL): Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
- Hyaluronic Acid (Monovisc®) (Type: ACTIVE_COMPARATOR): Single injection of sodium hyaluronate supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with locally invasive or metastatic, epithelial ovarian, fallopian tube, or primary peritoneal cancer~* Subjects must provide samples of tumor tissue~* Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Subjects with low-grade ovarian, fallopian tube, or Primary peritoneal cancer~* Women who are pregnant or breast feeding~* Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anetumab ravtansine (Type: EXPERIMENTAL): Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete